SEC Forn	n 4																	
I	FORM	4	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549													OMB APPROVAL		
 Section ' obligation Instruction Check the transaction contract, the purch securities to satisfy 	is box to indica on was made p instruction or v nase or sale of s of the issuer f the affirmative is of Rule 10b5	orm 5 e. See the that a sursuant to a written plan for equity that is intended defense	STA		led purs	suant t	o Sectior	n 16(a	ES IN BE	rities Exchar	nge Act of 1		HIP	Estima	Numbe ated av per res	erage burde	3235-0287 en 0.5	
1. Name and Address of Reporting Person [*] Khattar Jack A.						2. Issuer Name and Ticker or Trading Symbol <u>SUPERNUS PHARMACEUTICALS, INC.</u> [SUPN]							Relationship of Reporting Person(s) to Issuer heck all applicable) Image: state					
(Last)(First)(Middle)C/O SUPERNUS PHARMACEUTICALS INC.9715 KEY WEST AVENUE				12/	3. Date of Earliest Transaction (Month/Day/Year) 12/23/2024							below) below) President, CEO						
(Street) ROCKVILLE MD 20850					4. lf	4. If Amendment, Date of Original Filed (Month/Day/Year)							6. Individual or Joint/Group Filing (Check Applicable Line)					
(City)	(Sta	, ,	Zip)							<u> </u>	<u> </u>							
Table I - Non-Deriv. 1. Title of Security (Instr. 3) 2. Transa Date (Month/E)					saction	ar) if	A. Deeme xecution any Month/Day	d Date,	3. Transaction Code (Instr. 5)		ies Acquired (A) or Of (D) (Instr. 3, 4 and		5. Amount of		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)	
		т	able II -	Deriva	ative	Secu	rities /	Acqu	uired, Disj	posed of,	or Bene	ficially		nd 4)				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deem Execution if any (Month/Da	ed i Date,	te, 4. Code (Ir		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exer Expiration D (Month/Day/	cisable and ate	7. Title an of Securit Underlyin Derivative (Instr. 3 an	d Amount es g Security	8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	e s Illy g	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial) Ownership ct (Instr. 4)	
					Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	nber					
Performance Share Unit	\$0	12/23/2024			A		14,000		(1)	(1)	Common Stock	14,000	\$0	14,00	0	D		
Performance	\$0	12/23/2024			Α		38,640		(2)	(2)	Common	38,640	\$0	38,64		D		

1. On February 23, 2023, the Reporting Person was awarded Performance Share Units a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on June 12, 2023 and modified on December 12, 2024.

2. On February 22, 2024, the Reporting Person was awarded Performance Share Units a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on June 24, 2024.

Remarks:

/s/ Timothy C. Dec. as attorney-12/24/2024

in-fact

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.